Guizhounli Pharmaceutical Co (SHSE:603439) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co Additional Paid-In Capital?

Guizhounli Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥218 Mil) but then stayed the same from Dec. 2023 (¥218 Mil) to Mar. 2024 (¥0 Mil).

Guizhounli Pharmaceutical Co's annual additional paid-in capital stayed the same from Dec. 2021 (¥220 Mil) to Dec. 2022 (¥220 Mil) but then declined from Dec. 2022 (¥220 Mil) to Dec. 2023 (¥218 Mil).

Guizhounli Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co Additional Paid-In Capital Chart

Guizhounli Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

0.60

196.71

219.72

218.20

Guizhounli Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	219.92	-	218.20	-

Guizhounli Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Guizhounli Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Guizhounli Pharmaceutical Co (SHSE:603439) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000

Website

http://www.gz-sanli.com

Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.

Executives

Zhang Hong Yu	Directors, senior managers
Wang Yi	senior management
Zhang Qian Fan	Directors, senior managers
Sheng Yong Jian	Director

Guizhounli Pharmaceutical Co (SHSE:603439) Headlines

No Headlines